{"id":24260,"date":"2024-02-07T15:18:04","date_gmt":"2024-02-07T14:18:04","guid":{"rendered":"https:\/\/www.izb-online.de\/izb-biotech-news-morphosys-schliesst-vereinbarung-zur-uebernahme-durch-pharmakonzern-novartis\/"},"modified":"2024-02-07T15:36:41","modified_gmt":"2024-02-07T14:36:41","slug":"morphosys-enters-into-business-combination-agreement-to-be-acquired-by-medicines-company-novartis","status":"publish","type":"post","link":"https:\/\/www.izb-online.de\/en\/izb-biotech-news\/morphosys-enters-into-business-combination-agreement-to-be-acquired-by-medicines-company-novartis\/","title":{"rendered":"MorphoSys Enters into Business Combination Agreement to be acquired by medicines company Novartis"},"content":{"rendered":"

[vc_row el_class=”gco-magazine-container”][vc_column el_class=”bildspalte”][vc_row_inner][vc_column_inner offset=”vc_col-lg-12 vc_col-md-12″][vc_column_text el_class=”gco-magazine–title”]<\/p>\n

MorphoSys enters into Business Combination Agreement to be acquired by medicines company Novartis<\/h1>\n

[\/vc_column_text][vc_column_text el_class=”gco-magazine-lead”]Novartis intends to acquire MorphoSys AG for a total of \u20ac2.7 billion to strengthen its oncology pipeline[\/vc_column_text][vc_column_text el_class=”gco-magazine–post-date”]February, 2024[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner][vc_single_image image=”23724″ img_size=”full”][vc_column_text el_class=”gco-magazine-copyright”]\u00a9 MorphoSys[\/vc_column_text][vc_column_text el_class=”gco-magazine-picture-discription”]The medicines company Novartis wants to take over MorphoySys for 2.7 billion euros.[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine–quote” css=”.vc_custom_1611310713611{margin-top: 33px !important;}”][vc_column_inner][vc_column_text]<\/p>\n

\u201cNovartis shares our steadfast commitment to develop and deliver transformative medicines that address the dire needs of cancer patients.\u201d<\/h6>\n

Jean-Paul Kress, M.D., Chief Executive Officer of MorphoSys<\/p>\n

[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine-container–copy” css=”.vc_custom_1591795890737{margin-top: 21px !important;}”][vc_column_inner][vc_column_text]IZB-alumnus MorphoSys AG (FSE: MOR; NASDAQ: MOR)\u00a0announced on 5 February that it has entered into a Business Combination Agreement with Novartis based on Novartis\u2019 intention to submit a voluntary public takeover offer for all outstanding MorphoSys no-par value bearer shares at an offer price of \u20ac 68.00 per share in cash. As part of the Business Combination Agreement with Novartis, Novartis seeks to obtain exclusive, worldwide rights to develop and commercialize pelabresib, an investigational BET inhibitor, and tulmimetostat, an investigational next-generation dual inhibitor of EZH2 and EZH1, across all indications. Separately, MorphoSys entered into a Purchase Agreement to sell and transfer all rights worldwide related to tafasitamab to the biopharmaceutical company\u00a0Incyte. Currently, MorphoSys partners with Incyte on the development and commercialization of tafasitamab. MorphoSys\u2019 Management Board and Supervisory Board unanimously approved both agreements.<\/p>\n

\u201cNovartis shares our steadfast commitment to develop and deliver transformative medicines that address the dire needs of cancer patients. Pelabresib \u2013 the investigational therapy at the forefront of our promising oncology pipeline \u2013 has the potential to shift the treatment paradigm in myelofibrosis and further expand into other indications. Novartis will provide ample resources currently unavailable to MorphoSys as a standalone biotech company to help accelerate the development opportunities and maximize the commercialization potential of pelabresib at a greater speed and scale,\u201d said Jean-Paul Kress, M.D., Chief Executive Officer of MorphoSys. \u201cWe are also pleased that Incyte will assume full responsibility of tafasitamab. Given the proposed acquisition by Novartis and our long-standing partnership with Incyte, we know Incyte is best positioned to drive tafasitamab\u2019s future growth opportunities forward successfully and more efficiently on its own at this time. We believe these agreements are in the best interest of MorphoSys, our shareholders and cancer patients.\u201d<\/p>\n

Read more here<\/a><\/p>\n

About MorphoSys
\n<\/strong>At MorphoSys, we are driven by our mission: More life for people with cancer. As a global commercial-stage biopharmaceutical company, we develop and deliver innovative medicines, aspiring to redefine how cancer is treated. MorphoSys is headquartered in Planegg, Germany, and has its U.S. operations anchored in Boston, Massachusetts. To learn more, visit us at\u00a0www.morphosys.com<\/a>\u00a0and follow us on\u00a0Twitter<\/a> at X\u00a0and\u00a0LinkedIn<\/a>.[\/vc_column_text][vc_column_text css=”.vc_custom_1583761043671{background-color: #1e73be !important;}” el_class=”redaktionell”][\/vc_column_text][\/vc_column_inner][\/vc_row_inner]\n\n

\n \n \n
\n MorphoSys AG <\/div>\n\n